Cite
HARVARD Citation
Genovese, M. et al. (n.d.). OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study. Annals of the rheumatic diseases. pp. 75-76. [Online].